NEBULA: Transforming Drug Target Discovery with Physics-Based AI

Partnering to Unlock Dynamic Therapeutic Targets

At NEBULA, we provide an exhaustive view of the myriad shapes that therapeutic targets can adopt under physiological conditions. Our cutting-edge technology integrates physics-based generative genAI and physics to map the complete 3D structural landscape of macromolecules—without relying on pre-existing datasets. This comprehensive profiling enhances the accuracy of virtual screening, significantly increasing the chances of identifying effective drug candidates.

Our Innovations at a Glance

Unveiling Dynamic Target Structures

Discover the full range of therapeutic target shapes with NEBULA’s cutting-edge genAI with physics. We capture the dynamic nature of macromolecules, providing unprecedented insights for effective drug design.

Strategic Partnerships for Drug Discovery

Our partnership approach means we work alongside you, integrating our expertise with your projects. Together, we achieve more—enhancing outcomes without the limitations of traditional software licensing.

Speeding Up Drug Development

NEBULA accelerates your drug discovery process by enhancing predictive accuracy. Our comprehensive target profiling reduces development time, bringing effective treatments to market faster.

Witness Protein Dynamics in Action

See how voltage-gated sensors in proteins shift their shapes to regulate electrical signals in cells. Understanding these changes helps us design better drugs targeting neurological and cardiovascular diseases.
See how the P53 protein, known as the “guardian of the genome,” alters its structure. These insights are vital for developing cancer therapies targeting this key protein.
Watch the HIV protease enzyme as it flexes and shifts between different shapes. These movements are key to the virus’s ability to replicate. By mapping these conformations, we can discover new ways to inhibit the enzyme and develop more effective treatments for HIV.

Meet the Founders

See who is behind the company

Daniel Wiczew

An entrepreneur with deep expertise in artificial intelligence, biomedical sciences, and drug design. Daniel brings unparalleled technical knowledge to NEBULA, driving our technology’s development and application in drug discovery.

Mounir Tarek

A senior research director with extensive experience in molecular modeling and computational biophysics. Mounir leads NEBULA with a vision to transform the pharmaceutical industry through innovative AI technologies.

Brought to you by

Frequently Asked Questions

Q1: How does NEBULA’s technology differ from traditional drug discovery methods?

NEBULA’s AI-driven platform provides a comprehensive mapping of therapeutic target structures, capturing dynamic conformations that traditional methods often miss. This enhances the accuracy of virtual screening and increases the likelihood of identifying effective drug candidates.

Q2: How does NEBULA compare to AlphaFold in protein structure prediction?

While AlphaFold revolutionized protein science by predicting static 3D structures of proteins from amino acid sequences, it primarily provides a single, most probable conformation. Proteins in physiological conditions are dynamic and can adopt multiple conformations. NEBULA goes beyond static predictions by mapping the full spectrum of a protein’s possible shapes. This dynamic profiling offers deeper insights into how drugs can interact with targets in real-world conditions, enhancing the success rate of drug discovery.

Q3: Can NEBULA integrate with our existing drug discovery processes?

Absolutely. Our solutions are designed to complement and enhance your current workflows. We provide detailed target profiling that seamlessly integrates into your virtual screening and drug design processes.

Q4: How can pharmaceutical companies partner with NEBULA?

Pharmaceutical and biotech companies can partner with NEBULA through our flexible, project-based service model. We offer customized solutions tailored to the complexity of your therapeutic targets, including initial setup, milestone deliverables, and revenue-sharing agreements. This collaborative approach aligns our success with yours, fostering a strong partnership for mutual benefit.

Q5: What support does NEBULA provide during a project?

Our team offers comprehensive support, including expert consultation, detailed data analysis, and ongoing collaboration. We’re committed to ensuring optimal outcomes for your drug discovery efforts.

Stay Tuned for the Latest in Drug Target Innovation

Get in Touch

Send us a message!

We’d love to hear from you. Please fill out the contact form below, and we’ll get back to you promptly.

Follow on Social

You agree to receive email communication from us by submitting this form.